Trial reportSurgical endoscopy2025
Traction-assisted endoscopic submucosal resection (TA-ESD) for rectal neuroendocrine tumors: a randomized multi-center trial.
Trial report in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Tumor count and risk of lymph node metastasis in multiple rectal neuroendocrine tumors: an individual-level pooled analysis.World journal of surgical oncology · 2026Article
- Defining endoscopic candidacy for intermediate size rectal neuroendocrine tumors.World journal of gastroenterology · 2026Article
- Pre-cutting traction-assisted endoscopic submucosal dissection for rectal neuroendocrine tumors.Endoscopy · 2025Article
- Redefining therapeutic thresholds and global guidelines: Toward precision management of intermediate-sized rectal neuroendocrine tumors.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
aimEndoscopic resection is the first-line choice for the treatment of rectal neuroendocrine tumors (NETs). This study aimed to compare the efficacy and safety of a modified traction-assisted endoscopic submucosal resection (TA-ESD) and traditional endoscopic submucosal resection (ESD).
methodsIn this multi-center prospective randomized controlled trial, patients with small rectal NET(< 2 cm) were 1:1 randomized into TA-ESD or traditional ESD groups. The operation time was selected as the primary endpoint, while en bloc resection rate, R0 resection rate, complications, length of hospitalization were chosen as secondary endpoints.
resultsA total of 44 patients (22 TA-ESD and 22 ESD patients) were enrolled in this study, of which 40 patients (19 TA-ESD and 21 ESD patients) were pathologically confirmed rectal NET patients. The median operation time was shorter in the TA-ESD group than in the ESD group (7.3 (5.4-9.6) vs. 12.2 (7.8-21.0) minutes, Difference (95% CI) -4.5 (-10.0, -1.3), P = 0.0054). Furthermore, the rates of en bloc resection and R0 resection were 22 (100%) and 22 (100%) in TA-ESD group and ESD group, respectively. Perforation occurred in one patient in the ESD group during the operation and no postoperative complication was recorded in both groups.
conclusionCompared with traditional ESD, modified TA-ESD is more suitable for the treatment of small rectal NETs than traditional ESD due to its shorter operation time and improved R0 resection rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.